Loading...
Novel inhibitors of mutated KRAS G12C, such as sotorasib and adagrasib, have shown efficacy across the spectrum of solid tumors, including non–small-cell lung, colorectal, and pancreatic cancer. Because inhibition of KRAS G12C may be overcome by feedback activation of the EGFR receptor, dual targeting combining an EGFR inhibitor with a KRAS G12C inhibitor has been studied.
Investigators now report results of an industry-sponsored, open-label, phase 3 trial in which patients with mutated KRAS G12C metastatic colon cancer were randomized to treatment with oral sotorasib at a dose of 240 mg daily combined with panitumumab (6 mg/kg IV every two weeks), sotorasib at a dose of 960 mg daily plus panitumumab, or investigators' choice of standard car…